# Gilead Sciences, Inc.: insider transactions

SEC CIK 882095. Roles and transactions as reported on Form 4. Latest Form 4 filed 2025-02-21.

## Roles

| Company | Role | Transactions | First | Latest |
| --- | --- | ---: | --- | --- |
| [Arcus Biosciences, Inc.](/companies/rcus.md) | 10% owner | 4 | 2021-01-31 | 2025-02-18 |
| [Kalaris Therapeutics, Inc.](/companies/klrs.md) | 10% owner | 1 | 2023-06-27 | 2023-06-27 |

## Transactions: 5

Every transaction reported, newest first. Codes P and S are open-market purchases and sales. Reported price is as stated on the form.

| Date | Company | Transaction | Shares | Reported price | Value | Filing |
| --- | --- | --- | ---: | ---: | ---: | --- |
| 2025-02-18 | [Arcus Biosciences, Inc.](/companies/rcus.md) | Purchase (P) | 1,363,636 | $11.00 | $15.0m | [Form 4](/filings/0001062993-25-003084.md) |
| 2024-01-29 | [Arcus Biosciences, Inc.](/companies/rcus.md) | Purchase (P) | 15,238,095 | $21.00 | $320.0m | [Form 4](/filings/0001104659-24-008868.md) |
| 2023-06-28 | [Arcus Biosciences, Inc.](/companies/rcus.md) | Purchase (P) | 1,010,000 | $19.26 | $19.5m | [Form 4](/filings/0001104659-23-077015.md) |
| 2023-06-27 | [Kalaris Therapeutics, Inc.](/companies/klrs.md) | Purchase (P) | 2,930,870 | $3.75 | $11.0m | [Form 4](/filings/0001062993-23-014111.md) |
| 2021-01-31 | [Arcus Biosciences, Inc.](/companies/rcus.md) | Purchase (P) | 5,650,000 | $39.00 | $220.3m | [Form 4](/filings/0001104659-21-010972.md) |

Source: SEC EDGAR, Forms 4. Last ingested by Listed: Oct 31, 2026, 10:18 ET. No prices; not investment advice.